A study on BeMe Health, a behavioral health platform for teens, found that users engaged with the platform eight times on average over a month. The study was done in collaboration with Stanford University.
A new Stanford study revealed that among Medicaid patients who had never taken an opioid, 30% developed an opioid dependency following their first prescription. The research showed that opioids that have historically marketed as "safe," such as tramadol, actually carry quite a high addiction risk for vulnerable populations.
Biotech startup Pheast Therapeutics is out of stealth taking a tack similar to that of cancer immunotherapy company Forty Seven, also a spinout from the Stanford University lab of Irving Weissman. While both companies get immune cells to eat tumors, Pheast’s technology has the potential to take the approach to a broader range of cancer types including those that have historically resisted immunotherapy.
A panel at the WSGR Medical Device Conference in San Francisco delved into the specifics around what oftentimes sinks the relationship between companies and colleges and how to create real alignment and understanding between the two stakeholders.
It was a banner year for biopharma, with records broken in deal values, number of exited unicorns and the biggest-ever biotech IPO. But where do these unicorn valuations come from?
Peer review is important for ensuring transparency and trust and may have put a stop to Theranos before it became a darling of investors and the press, the lead study author said in an interview.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The company uses machine learning-based analysis of clinical data to help fertility clinics provide personalized patient reports with success probabilities for potential IVF participants.
At the Stanford Medicine X conference, Dana Lewis, a vocal diabetes e-patient announced a research study funded by Robert Wood Johnson Foundation that she leads as principal investigator.
Few of the hundreds of mobile apps for cancer survivors were appropriately developed or tested, according to a new study by researchers from the Cancer Prevention Institute of California.
Exponential advances in health and other technologies have both deep risk and reward and the choices we make will create the future.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The researchers’ next goal is to make a more integrated system so that the processing is done on the phone so the user can see the results as soon as testing is done.
Cala Health, a Stanford spinout operating in stealth, has raised $18 million - seemingly to advance its wearable technology that treats hand and wrist tremors.
Researchers at Oregon Health and Science University and Stanford University have found that there is a protein common in the majority of cells that transports genetic material from a cell's outer wall to the interior - a breakthrough in gene therapy.
Fledgling startup LogicBio Therapeutics has raised $4 million from OrbiMed Advisors for its hemophilia gene therapy therapeutic candidate.
#DonateMyParts = organ donation via social media.
